U.S. markets close in 1 hour 59 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
538.85-16.94 (-3.05%)
As of 2:01PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close555.79
Bid542.35 x 1800
Ask543.17 x 800
Day's Range533.23 - 556.00
52 Week Range307.44 - 664.64
Avg. Volume862,238
Market Cap57.329B
Beta (5Y Monthly)0.50
PE Ratio (TTM)20.86
EPS (TTM)25.83
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est675.58
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
16% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Editor's Pick
    Yahoo Finance Video

    Coronavirus Latest: Thursday, October 29

    New, daily, U.S. coronavirus cases hit 80,000 on Thursday, with Regeneron posting positive results from its antibody cocktail trial, Moderna saying it is ‘actively preparing’ for a global launch of it vaccine, and Gilead announcing it sold $873 million dollars worth of its antiviral treatment. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.

  • What's in the Cards for Regeneron's (REGN) Q3 Earnings?

    What's in the Cards for Regeneron's (REGN) Q3 Earnings?

    Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports third-quarter 2020 results.

  • MarketWatch

    Regeneron says IDMC recommends halt of some REGN-COV2 trial enrollment for safety risks

    Shares of Regeneron Pharmaceuticals Inc. slumped 1.2% in morning trading Friday, after the biotechnology company said an independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 recommended that the patient trial be "modified," with the enrollment of some patients place on hold. REGN-COV2 was one of the treatments prescribed to President Trump after he tested positive for COVID-19. Based on a "potential safety signal and an unfavorable risk/benefit profile at this time," the IDMC recommended that further enrollment of patients requiring high-flow oxygen or mechanical ventilation be placed on hold pending analysis of further data. The IDMC also recommends continuing enrollment of patients requiring no or low-flow oxygen and the continuation of the outpatient trial without modification. REGN-COV2 is currently being evaluated by the Food and Drug Administration for a potential Emergency Use Authorization in mild-to-moderate outpatients with high risk of poor outcomes. The stock has lost 13% over the past three months, while the S&P 500 has gained 1.6%.